Singapore markets open in 34 minutes

Straits Times Index
3,187.66
+32.97(+1.05%)
S&P 500
5,011.12
-11.09(-0.22%)
Dow
37,775.38
+22.07(+0.06%)
Nasdaq
15,601.50
-81.87(-0.52%)
Bitcoin USD
63,042.82
+1,945.41(+3.18%)
CMC Crypto 200
1,306.49
+420.96(+47.27%)

23andMe Holding Co. (ME)

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Add to watchlist

0.5055

+0.1493

(+41.91%)

At close: 04:00PM EDT

0.5500

+0.04

(+8.80%)

After hours:

07:59PM EDT

Trade prices are not sourced from all markets

All

GlobeNewswire
23andMe announces CEO’s intention to pursue a potential take-private
SOUTH SAN FRANCISCO, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has been made aware that Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, is considering making a proposal to acquire all of the outstanding shares of 23andMe that she does not currently own, as she stated in an amendment dated April 17, 2024 to her Schedule 13D filing with the Securities and E
Reuters
23andMe CEO Wojcicki considering taking firm private, filing shows
Last week, Wojcicki notified members of the board's special committee that she is considering a potential go-private transaction for 23andMe and indicated that she would begin speaking to partners and financing sources. 23andMe declined to comment on the filing and Wojcicki did not immediately respond to a Reuters' request for comment. 23andMe, best known for its saliva-based test kits that offer users a glimpse into their genetic ancestry went public in 2021 through a blank-check firm, backed by Virgin Group founder Richard Branson, in a deal that valued the merged entity at $3.5 billion.
Simply Wall St.
Can 23andMe Holding (NASDAQ:ME) Afford To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...